Hansoh BioMedical R&D Company is advancing HS-20093, a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3, in combination with HRS-5041, a PROTAC targeting androgen receptors, for the treatment of advanced prostate cancer. This dual-target approach may provide a competitive edge in a market characterized by a high unmet need for effective therapies in metastatic castration-resistant prostate cancer (mCRPC). The study's focus on safety, tolerability, and pharmacokinetics will be critical in establishing the therapeutic profile and potential market positioning. Given the increasing incidence of prostate cancer and the limitations of current therapies, successful outcomes could lead to significant commercial opportunities, particularly in regions with high disease prevalence.